Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company whose news flow centers on the development of its INTASYL® gene silencing technology and lead compound PH-762. Company announcements describe INTASYL as a gene silencing platform focused on immuno-oncology therapeutics, with PH-762 targeting the PD-1 gene implicated in various forms of skin cancer.
News about Phio frequently covers clinical trial milestones for PH-762. The company has reported completion of enrollment in its ongoing Phase 1b dose escalation trial (NCT 06014086), interim pathology results in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and safety reviews by its Safety Monitoring Committee. Updates have included detailed response rates, such as complete, near complete, and partial responses based on tumor clearance, as well as statements that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed in the cohorts reported.
Phio also issues regulatory and development updates, including acceptance by the U.S. Food and Drug Administration of its nonclinical protocol study design for a toxicology study required before a pivotal trial of PH-762. Additional news items describe agreements with a U.S. manufacturer for cGMP clinical supply of PH-762 and progress toward delivering commercially viable drug product.
Investors following PHIO news will also see financing and corporate announcements, such as warrant inducement transactions, cash runway commentary, and board-level changes, including the appointment of a Lead Independent Director. The company regularly participates in investor conferences and scientific meetings, where it presents INTASYL technology and PH-762 data, and has highlighted external recognition such as PH-762 being named “Immunomodulatory Solution of the Year” in the BioTech Breakthrough Awards.
This news page aggregates these clinical, regulatory, financing, and governance updates so readers can track how Phio’s INTASYL platform and PH-762 program are progressing over time.
Phio Pharmaceuticals (NASDAQ: PHIO) entered a cGMP U.S. drug product manufacturing services agreement to supply its lead siRNA candidate PH-762 for clinical and potential commercial use. The move supports next-stage trials for intratumoral treatment of cutaneous carcinomas and secures domestic capacity for clinical supply.
Phio reported Phase 1b data: 22 patients treated with no dose-limiting toxicities, ~65% pathological response in cSCC across cohorts, and 85% response in the highest-dose cohort. FDA engagement is targeted for Q2 2026; cash runway is projected into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present Phase 1b clinical results for PH-762 at the American Academy of Dermatology Late-Breaking Research Session on March 28, 2026 at 3:00 PM MDT in Denver. The presentation reports 22 patients treated across five dose cohorts, no dose-limiting toxicities or serious adverse events, ~65% pathological response in cSCC overall and 85% response in the highest-dose cohort. FDA engagement for next-stage development is targeted for Q2 2026; cash runway is projected into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in a virtual fireside chat with Force Family Office on March 18, 2026 at 4 PM EDT to discuss its INTASYL gene‑silencing approach to immuno‑oncology.
Key clinical updates: lead candidate PH‑762 is in a Phase 1b intratumoral program (22 patients treated), with no dose‑limiting toxicities or serious adverse events, an overall pathological response in cSCC of ~65% and an 85% pathological response (6 of 7) in the highest dose cohort. The company targets FDA engagement in Q2 2026 and reports cash to sustain operations into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present live at the Life Sciences Investor Forum on March 12, 2026 at 11:00 AM ET. CEO Robert Bitterman will review the INTASYL siRNA platform, recent clinical progress for PH-762 and host a live Q&A. Replays and 1x1 meetings are available March 16–17. The company reported Phase 1b data showing ~65% pathological response in cSCC across doses, 85% (6 of 7) at the highest dose, no dose-limiting toxicities, planned FDA engagement in Q2 2026, and cash runway into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) reported 2025 year-end results and a business update. Key milestones include completion of the Phase 1b dose‑escalation for lead candidate PH‑762 with favorable safety and pathology signals, strengthening the balance sheet via financings and warrant exercises that generated $23.7 million in net proceeds, and cash of approximately $21.0 million at December 31, 2025.
The company advanced CMC and toxicology work, secured cGMP drug substance services, initiated a non‑clinical toxicology agreement, and targets an FDA meeting in Q2 2026 to seek guidance on next clinical steps.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at Renmark's Virtual Non-Deal Roadshow on March 9, 2026 at 10 AM EDT to review its INTASYL siRNA platform and recent clinical progress for lead candidate PH-762.
In a Phase 1b trial, 22 patients completed treatment with no dose-limiting toxicities or serious adverse events; reported pathological response in cSCC was ~65% overall and 85% (6 of 7) in the highest-dose cohort. FDA engagement is targeted for Q2 2026. Cash is projected to sustain operations into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) announced leadership changes to support upcoming regulatory engagements and clinical milestones for PH-762 while continuing development of PH-894. Lisa Carson was promoted to Chief Financial Officer, Jennifer Phillips, Pharm.D., to Senior Vice President, Regulatory and Corporate Affairs, and Kimberly Man joined as Vice President of Program Development.
These appointments emphasize enhanced finance, regulatory strategy, and program coordination as the company prepares for the next stage of PH-762 clinical development.
Phio Pharmaceuticals (NASDAQ: PHIO) reported that the Safety Monitoring Committee completed its safety review of PH-762 in a Phase 1b skin cancer trial. No dose-limiting toxicities or serious adverse events were observed among 22 treated patients across five dose-escalation cohorts.
The highest dose cohort (n=7) showed an 85% pathological response (6 of 7), with 4 of 6 responders achieving complete tumor clearance. Overall cSCC response was 65% (13 of 20), including 9 complete responses. An FDA meeting submission is targeted for Q2 2026 and CMC API material is expected in March 2026 ahead of cGMP manufacturing in H2 2026.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the 3rd Annual DealFlow Discovery Conference on January 28, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman, will deliver the company presentation on January 28 at 9:00 AM ET in Borgata Hotel Room #1, and management will be available for one-on-one investor meetings during the event.
The company noted completion of treatment in the Phase 1b trial for PH-762 and emphasized ongoing development of therapeutics using its proprietary INTASYL gene silencing technology targeting cancer.
Phio Pharmaceuticals (NASDAQ: PHIO) reported pathology and safety results from its Phase 1b intratumoral PH-762 dose‑escalation trial in cutaneous carcinomas on January 20, 2026. Across five cohorts, 22 patients completed treatment and excision; among 20 cSCC patients, 14 were pathologic responders (70% overall response): 10 complete responses (100% clearance), 2 near‑complete (>90%), and 2 partial (>50%). One metastatic Merkel cell patient had a partial (>50%) response. No dose‑limiting toxicities or clinically relevant treatment‑emergent adverse events were observed through the reported follow‑up. Drug concentration was escalated 20‑fold from first to final cohort. Extended safety follow‑up is expected in Q2 2026 and follow‑on trial design is underway.